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CD28 CONTROLS DIFFERENTIATION OF REGULATORY T CELLS FROM
NAIVE CD4 T CELLS
Yu, X.-Z.1,2, Guo, F.1, Iclozan, C.1, Suh,W.-K.3, Anasetti, C.1,2 1H. Lee
Moffitt Cancer Center & Research Institute, Tampa, FL; 2University of
South Florida, Tampa, FL; 3 Institut de Recherches Cliniques de
Montreal, Montreal, QC, Canada.
CD28 is required for the development of regulatory T cells
(Tregs, CD41CD251Foxp31) in the thymus and also contributes
to their survival and homeostasis in the periphery. We studied
whether and how CD28 and ICOS control the differentiation of
Tregs from naive T cells. By using WT, CD28-, ICOS- or
CD28/ICOS-knockout mice on C57BL/6 background as T-cell
sources, we found that CD28 is essential, while ICOS is dispensable,
for the development and homeostasis of Tregs as well as for the
generation of Tregs from naive CD41CD25- T cells in vivo. The
requirement of CD28 for Treg differentiation was mediated by
IL-2, because neutralization of IL-2 with its specific mAb blocked
Treg differentiation fromwild-type CD41CD25-T cells and addi-
tion of IL-2 restored Treg differentiation from CD28-/- T cells.
Other commong-chain cytokines, IL-4, IL-7 or IL-15, do not share
such a role of IL-2. However, a strong CD28-signal promotes ex-
pansion of T effector cells (CD251Foxp3-) while inhibiting differ-
entiation of Tregs. Our study demonstrates that CD28 delicately
controls the process of Treg differentiation and T effector cell ex-
pansion in the periphery, which provides the ‘‘fine-tuning’’ of the
balance between immune activation and suppression.AUTOLOGOUS TRANSPLANTSNo Steroid
(n 5 16)
Steroid
# D12
(n 5 7)
Steroid
. D12
(n 5 7) P
P, early
vs late CS
Weight change, % 0.6 (0.4.2–6.7) 6.7 (3.6–27.2) 11.2 (22.1–23.2) 0.005 NS
Rash, % 27 71 43 NS NS
Diarrhea, % 73 86 86 NS NS
Tmax, C 39 (37.8–41) 40.1 (39–41.1) 38.9 (38.7–40.8) 0.08 0.07
1st fever, day 10 (6–15) 8 (7–9) 12 (8–146) 0.007 0.007
Abnormal CXR1, % 13 71 71 0.03 NS
Ventilator, % 0 14 71 0.004 0.03
ANC500, day 15 (12–29) 16 (14–115) 18 (15–45) 0.08 NS
PLT20, day 12 (8–41) 20 (11–115) 24 (9–170) 0.05 NS
PLT50, day 15 (11–192) 32 (16–115) 56 (13–551) 0.03 NS
RBCs, units 3 (2–8) 6 (4–31) 11 (6–64) 0.0008 NS
PLTS, apheresis units 2 (1–9) 9 (4–51) 18 (4–60) 0.0004 NS
Hospital dismissal, day 15 (13–36) 21 (15–69) 41 (16–175) 0.009 0.0586
LONG-TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANT
(ASCT) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
Al-Farsi, K., Zadeh, S., Nagy, T., Franke, N., Keating, A., Crump, M.,
Kuruvilla, J. Princess Margaret Hospital, Toronto, ON, Canada.
Introduction: MCL is considered incurable with conventional
therapy. ASCT has been shown to prolong progression free sur-
vival. However, reported median follow-up is generally short. We
report a review of the outcome of patients (pts) with MCL who un-
derwent ASCT at our institution with longer follow-up (f/u).
Method: From May 1987 – Jul 2006, 47 pts underwent ASCT
for advanced stage MCL, 43 of whom had adequate f/u data and
were subsequently analyzed for outcome. Results: At ASCT, me-
dian age: 53 years (range 34–65), 36 males, CR: 21, PR: 22. 12 pts
were transplanted beyond first CR or PR (.CR/PR1). Primary
therapy: CHOP (n5 37; R-CHOP: 9) and other combination che-
motherapy: 6. Salvage therapy in .CR/PR1: 7 had DHAP, 3
CHOP, 1 mini-BEAM and 1 ESHAP. 21 pts had rituximab before
(11 with first line or salvage and 10 with mobilizing chemotherapy)
and 11 had maintenance after ASCT. High dose regimen: CBV: 9,
VP16/Melphalan/TBI 12Gy: 27 or VP16/Melphalan: 11. Stem cell
source: peripheral blood: 40, bonemarrow: 2 andmixed: 1. Progres-
sive disease (PD) occurred in 21 pts; median time to progression
post ASCT: 25 m. 32 pts remain alive (22 in CR, 10 have relapsed),
while 11 pts have died of PD. No transplant related deaths. 4 pts de-
veloped secondary malignancies: 1 MDS, 1 skin (basal cell), 2 lung
and 1 breast cancers. With a median f/u of 57 months from ASCT,
median PFS was 42mwhile medianOS has not been reached (5 year
OS: 65%). Of pts who have not relapsed, 7 continue to be alive and
disease free. 5 years after ASCT. Univariate analysis identified the
use of rituximab before and/or after ASCT (p 5 0.047) and ASCT
inCR/PR1 (p5 0.001) as being statistically significant predictors of
improved OS with only ASCT in CR/PR1 remained significant in
multivariate analysis. For PFS, maintenance rituximab post-34ASCT (p5 0.03) and ASCT in CR/PR1 (p5 0.01) were significant
on univariate analysis with ASCT in CR/PR1 remaining significant
in themultivariatemodel (median PFS of 12m in.CR/PR1 vs. 62m
in CR/PR1, p5 0.008).Conclusion: ASCT can achieve prolonged
remissions inMCLwith some pts having remission duration of over
5 years. Pts transplanted in first remission appear to have superior
PFS and OS compared to those transplanted in later
stages. Seconds cancers may be a concern with longer follow-up.
A significant number of pts relapse after ASCT, necessitating the
exploration of more effective treatment strategies such as the incor-
poration of rituximab before and/or after ASCT.87
PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR POEMS SYNDROME
IS ASSOCIATED WITH HIGH RATES OF ENGRAFTMENT SYNDROME
Dispenzieri, A.1, Lacy, M.Q.1, Hayman, S.R.1, Kumar, S.K.1,
Buadi, F.1, Dingli, D.1, Litzow, M.R.1, Gastineau, D.A.1,
Inwards, D.J.1, Elliott, M.A.1, Micallef, I.N.1, Ansell, S.M.1,
Hogan, W.J.1, Porrata, L.F.1, Johnston, P.B.1, Afessa, B.2, Bryce, A.1,
Kyle, R.A.1, Gertz, M.A.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic,
Rochester, MN.
Background: POEMS syndrome is a devastating syndrome,
characterized by peripheral neuropathy, organomegaly, endocrin-
opathy, monoclonal plasma cells, skin changes, papilledema, vol-
ume overload, sclerotic bone lesions, thrombocytosis, and high
VEGF.High-dose chemotherapy with autologous peripheral blood
stem cell transplantation (ASCT) ultimately yields excellent clinical
responses, but there can be considerable peri-transplant morbidity.
Methods: Thirty patients with POEMS syndrome have been
treated with PBSCT at the Mayo Clinic Rochester, 11 of whom
have been previously reported. We retrospectively studied treat-
ment outcomes, with an emphasis on treatment related morbidity.
The definitions of engraftment syndrome (ES) used were of Spitzer
(BMT, 27:893–8 2001) and Maiolino et al (BMT, 31:393–397,
2003). Results: Of the 30 patients, two-thirds were male. Median
age was 48, range 20–60. The median time from the first symptoms
and from the diagnosis of POEMS syndrome was 26 and 4 months,
respectively. Patients had a median of 2 prior treatments (range 0–
6). The median number of units of RBCs and apheresis platelets
transfused were 6 and 5. During transplant period, patients had
high rates of fever, diarrhea, weight gain, and rash (93%, 77%,
53%, and 43%, respectively). Only 13% remained outpatient, and
median time to discharge from hospital was transplant day 17 (range
0–175). Factors that predicted for longer than median dismissal
times included age (p 5 0.04), abnormal chest radiograph 7 to 17
days post transplant (p\0.0001), and bolus corticosteroids beyond
day 12 post-transplant (p 5 0.006). Splenomegaly was the baseline
factor that best predicted for a complicated peri-transplant course.
